SCHEMBL3487237

SCHEMBL3487237

O=C(O)c1ccc(-c2ccc(-c3cc4ccccc4o3)[nH]2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 1/20 0.49
▸ KDM4C Q9H3R0 1/20 0.49
▸ KDM5B Q9UGL1 1/20 0.49
▸ TNKS O95271 1/20 0.49
▸ CSNK2A1 P68400 1/20 0.48
▸ RAB9A P51151 5/20 0.47
▸ NPC1 O15118 4/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ NPY1R P25929 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ ALOX5 P09917 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980203 0.84 TNKS (0.66) TNKSCSNK2A1RAB9ANPC1SMN1; SMN2
SCHEMBL7618483 0.83 KDM4E (0.46) RAB9ANPC1KDM4EALDH1A1KMT2A
SCHEMBL7618637 0.81 RARA (0.50) TNKSRAB9ANPC1MAOBMAOA
SCHEMBL7624863 0.80 MAOB (0.51) RAB9ANPC1MEN1KMT2AMAOB
SCHEMBL7625464 0.80 RARA (0.44) RAB9ANPC1RARARARBRARG
SCHEMBL7625527 0.80 TNKS (0.48) TNKSRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7618545 0.80 TNKS (0.48) TNKSRARARARBRARGNQO2
SCHEMBL7628810 0.78 RARA (0.54) KDM4EALDH1A1KMT2AMAPTRARA
SCHEMBL7725462 0.78 RARA (0.41) TNKSKDM4EALDH1A1KMT2AMAPT
SCHEMBL7618653 0.78 RARA (0.42) RAB9ANPC1TP53MAPTRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100063162-A1 METHOD FOR PREDICTING EFFICACY OF RAR-ALPHA AGONIST TAIHO PHARMACEUTICAL CO., LTD. (JP) 2010-03-11 — — US disclosed
EP-1950293-A1 METHOD FOR PREDICTION OF EFFECTIVENESS OF RAR- AGONIST Taiho Pharmaceutical Co., Ltd. (JP) 2008-07-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063162-A1 METHOD FOR PREDICTING EFFICACY OF RAR-ALPHA AGONIST RARA, RARB, RARG KDM5A 3610/4885KDM4C 4295/4885KDM5B 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback